Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

DermoSafe 2.0

Financiado

An Integral Platform for the Early Diagnosis of Skin Cancer

DermoSafe® is an integral platform based on DermoBrain, a cognitive computing system which will enable the early detection of skin cancer for broad population. The ICT-based approach facilitates and speeds the professional analysi... ver más

31/03/2019

DermoSafe SA

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

DermoSafe SA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-03-31

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 6 años

0% 100%

2 Participantes

DermoSafe SA

50.00K€ | Lider

AEV IBERICA

344.96K€ | Participante

Últimas noticias

27-11-2024: Videojuegos y creaci... Se abre la línea de ayuda pública: Ayudas para la promoción del sector del videojuego, del pódcast y otras formas de creación digital

27-11-2024: DGIPYME En las últimas 48 horas el Organismo DGIPYME ha otorgado 1 concesiones

27-11-2024: FUNDACION-EOI En las últimas 48 horas el Organismo FUNDACION EOI ha otorgado 2 concesiones

Duración del proyecto: 4 meses Fecha Inicio: 2018-11-19
Fecha Fin: 2019-03-31

Líder del proyecto

DermoSafe SA

TRL 4-5

Presupuesto del proyecto 71K€

Descripción del proyecto DermoSafe® is an integral platform based on DermoBrain, a cognitive computing system which will enable the early detection of skin cancer for broad population. The ICT-based approach facilitates and speeds the professional analysis of potential skin lesion by employing Dermoscopy Imaging. DermoSafe provides an accurate tool that allows patient performing the needed increased analysis to combat the exploded incidence of skin cancer without the requirement of an appointment with general practitioners or dermatologists, reducing lead time of the skin analysis results from 42 to 3 days. Hence, patient uncertainty and anxiety is clearly diminished. Furthermore, DermoSafe enables a fast and easy access to Dermoscopy experts to the healthcare professional community (pharmacies, general practitioners and dermatologists). DermoSafe has demonstrated capability to overpass the limitations posed by current Dermoscopy devices for early and broad screening by avoiding the need of a high investment to buy the equipment as well as offsets the lack of specialised dermatology workforce. Once implemented in the healthcare system and at pharmacies, DermoSafe can reduce the skin cancer budget up to 136,000€/patient. Since our platform and associated service will make the use of Dermoscopy imaging as broad as the use of a thermometer, the business opportunity seems unquestionable. The objective of this project is the further development of DermoBrain, to enable (1) skin lesion pattern recognition and identification for automatic history tracking and evolution rating, (2) automatic image quality check, and (3) image automatic classification considering also the patient medical context by artificial intelligence. By deploying DermoSafe platform in Europe, we aim to achieve a cumulative cash flow of 10.7 M€ by 2024, resulting in a ROI of 4.2

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores